Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
- 1 March 2008
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (7) , 1119-1127
- https://doi.org/10.1200/jco.2007.13.1128
Abstract
Purpose To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine ki...Keywords
This publication has 42 references indexed in Scilit:
- Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung CancersPLoS Medicine, 2007
- Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Multidrug Transporter ABCG2 Prevents Tumor Cell Death Induced by the Epidermal Growth Factor Receptor Inhibitor Iressa (ZD1839, Gefitinib)Cancer Research, 2005
- An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor InhibitorsCancer Research, 2004
- Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in MiceCancer Research, 2004
- Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4JNCI Journal of the National Cancer Institute, 2002
- Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4JNCI Journal of the National Cancer Institute, 1999
- Interindividual Differences in Hepatic Expression of CYP3A4: Relationship to Genetic Polymorphism in the 5′-Upstream Regulatory RegionBiochemical and Biophysical Research Communications, 1999
- Cloning of a Variant Epidermal Growth Factor ReceptorBiochemical and Biophysical Research Communications, 1993